Interactive Features

Quiz

Nab-paclitaxel Plus Gemcitabine-Cisplatin by Primary Location of Biliary Tract Cancer

02/10/2023

Although it did not meet its primary end point of improved overall survival, the phase 3 SWOG 1815 trial suggested gemcitabine-cisplatin plus nab-paclitaxel may show benefit in which primary tumor location of biliary tract cancer?

Although it did not meet its...

02/10/2023

Oncology

Quiz

Quiz: Outcomes of Liver Transplant vs Resection for Perihilar Cholangiocarcinoma

12/01/2022

How did the outcomes of patients with unresectable perihilar cholangiocarcinoma who were treated with neoadjuvant chemoradiotherapy and liver transplant compare to the outcomes of patients with perihilar cholangiocarcinoma who underwent...

How did the outcomes of patients...

12/01/2022

Oncology

Quiz

Quiz: Trastuzumab Biosimilar Plus FOLFOX for HER2-Positive Biliary Tract Cancer

11/30/2022

What was the approximate objective response rate seen for patients with HER2-positive biliary tract cancer treated with the trastuzumab-pkrb biosimilar plus modified FOLFOX chemotherapy in the second- or third-line setting?

What was the approximate...

11/30/2022

Oncology

Quiz

Quiz: In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with intrahepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

11/02/2022

In the phase 2 FIDES-01 study, derazantinib showed clinical benefit in patients with interhepatic cholangiocarcinoma and which types of FGFR2 genetic mutations, aberrations, or fusions?

In the phase 2 FIDES-01 study,...

11/02/2022

Oncology

Quiz

True or False: In the phase 2 FIDES-01 study, derazantinib was found to have a comparable toxicity profile to other FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib.

10/21/2022

In the phase 2 FIDES-01 study, was derazantinib found to have a comparable toxicity profile to other small molecule, FGFR-inhibitors such as pemigatinib, infigratinib, and futibatinib?

In the phase 2 FIDES-01 study,...

10/21/2022

Oncology

Quiz

Quiz: Durvalumab Added to Gemcitabine-Cisplatin for Biliary Tract Cancers

09/02/2022

In the TOPAZ-1 trial which determined whether the addition of durvalumab to gemcitabine-cisplatin chemotherapy conferred a survival benefit for patients with advanced or metastatic biliary tract cancers, which primary tumor location saw...

In the TOPAZ-1 trial which...

09/02/2022

Oncology

Test Your Knowledge

Quiz: What Test Can Be Used to Compare OS, DFS in ICC?

02/24/2022

Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?

Which test can be used to...

02/24/2022

Oncology

Test Your Knowledge

Quiz: What Test Can Be Used to Compare OS, DFS in ICC?

02/24/2022

Which test can be used to compare overall survival (OS) and disease-free survival (DFS) in intrahepatic cholangiocarcinoma (ICC)?

Which test can be used to...

02/24/2022

Oncology

Quiz

Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?

02/14/2022

The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.

The FDA’s approval of...

02/14/2022

Oncology

Quiz

Quiz: Which Clinical Trial Was the Basis for Pemagatinib Approval?

02/14/2022

The FDA’s approval of pemigatinib was based on a clinical trial of 107 pretreated patients with locally advanced or metastatic cholangiocarcinoma and _____ fusion or rearrangement.

The FDA’s approval of...

02/14/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology